177 related articles for article (PubMed ID: 8759604)
1. Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Cornarotti M; Capranico G; Bohm S; Oriana S; Spatti GB; Mariani L; Ballabio G; Zunino F
Int J Cancer; 1996 Aug; 67(4):479-84. PubMed ID: 8759604
[TBL] [Abstract][Full Text] [Related]
2. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Giaccone G; van Ark-Otte J; Scagliotti G; Capranico G; van der Valk P; Rubio G; Dalesio O; Lopez R; Zunino F; Walboomers J
Biochim Biophys Acta; 1995 Dec; 1264(3):337-46. PubMed ID: 8547322
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase II alpha expression in squamous cell carcinomas of the head and neck.
Stathopoulos GP; Kapranos N; Manolopoulos L; Papadimitriou C; Adamopoulos G
Anticancer Res; 2000; 20(1A):177-82. PubMed ID: 10769652
[TBL] [Abstract][Full Text] [Related]
5. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
van der Zee AG; Hollema H; de Jong S; Boonstra H; Gouw A; Willemse PH; Zijlstra JG; de Vries EG
Cancer Res; 1991 Nov; 51(21):5915-20. PubMed ID: 1682037
[TBL] [Abstract][Full Text] [Related]
7. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
9. Genetic diagnosis for chemosensitivity with drug-resistance genes in epithelial ovarian cancer.
Naniwa J; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(1):76-82. PubMed ID: 17291235
[TBL] [Abstract][Full Text] [Related]
10. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.
Harker WG; Slade DL; Parr RL; Feldhoff PW; Sullivan DM; Holguin MH
Cancer Res; 1995 Apr; 55(8):1707-16. PubMed ID: 7712479
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
12. Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Li L; Luan Y; Wang G; Tang B; Li D; Zhang W; Li X; Zhao J; Ding H; Reed E; Li QQ
Int J Mol Med; 2004 Aug; 14(2):257-64. PubMed ID: 15254775
[TBL] [Abstract][Full Text] [Related]
13. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
15. [Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor].
Zhang WY; Pan Y; Zhu LR; Zhang JZ; Zhang M; Feng K; Zhou L; Yu L; Zhang XM; Ng SW
Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2988-91. PubMed ID: 16324386
[TBL] [Abstract][Full Text] [Related]
16. Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
Hasegawa T; Isobe K; Nakashima I; Shimokata K
Biochem Biophys Res Commun; 1993 Aug; 195(1):409-14. PubMed ID: 8395833
[TBL] [Abstract][Full Text] [Related]
17. Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Kim R; Ohi Y; Inoue H; Toge T
Anticancer Res; 1999; 19(6B):5393-8. PubMed ID: 10697567
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
19. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
20. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]